ERBB2 and COVID-19: In an Italian series of cancer patients infected with COVID-19 in a 1-month duration, BC patients represented five of 17 patients, of whom two were on chemotherapy, one was on adjuvant endocrine therapy and two patients were on mTOR inhibitors or an anti-Her2 agent in the metastatic setting [20].